Lv38
270 积分 2023-08-09 加入
T cell engagers: expanding horizons in oncology and beyond
21小时前
待确认
Shaping secondary pharmacology panels of the future: evolving target selection criteria for safety panels
5天前
已完结
ILC3 in Axial Spondyloarthritis: the Gut Angle
28天前
已完结
Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double‐blind, placebo‐controlled, phase III trial
29天前
已完结
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
29天前
已完结
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
29天前
已完结
Autoimmunity-associated T cell receptors recognize HLA-B*27-bound peptides
1个月前
已完结
The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTA
1个月前
已完结
Axial Spondyloarthritis
1个月前
已完结
Efficacy and Safety of Sunvozertinib Monotherapy as First-line Treatment in NSCLC Patients with EGFR Exon 20 Insertion Mutations: A Phase 2, Single-center Trial
1个月前
已完结
皖公网安备34019202002308
